Investigational New Drug

Pic:getty/stockcolors

AffaMed Therapeutics obtains IND clearance for novel retinal biologic

By Rachel Arthur

AffaMed Therapeutics has announced that the US FDA has cleared its Investigational New Drug (IND) application for the clinical development of AM712 (ASKG712), a novel proprietary bispecific biologic molecule blocking both vascular endothelial growth factor...

CFDA accepts WuXi-MedImmune’s IND for new mAb

CFDA accepts WuXi-MedImmune’s IND for new mAb

By Zachary Brennan

The China Food and Drug Administration (CFDA) has accepted for review an Investigational New Drug (IND) application for WuXi and MedImmune's novel anti-IL6 monoclonal antibody (mAb) for rheumatoid arthritis. 

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers